CA
WST icon

Crewe Advisors’s West Pharmaceutical WST Stock Holding History

Crewe Advisors’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-93
Closed -$30.6K – 1004
2024
Q2 		$30.6K Buy
93
+71
+323% +$25.1K ﹤0.01% 466
2024
Q1 		$8.71K Buy
+22
New +$8.14K ﹤0.01% 641
2023
Q3 		– Sell
-5
Closed -$1.91K – 930
2023
Q2 		$1.91K Sell
5
-60
-92% -$21.4K ﹤0.01% 540
2023
Q1 		$22.5K Hold
65
– – ﹤0.01% 409
2022
Q4 		$15.3K Buy
65
+54
+491% +$12.8K ﹤0.01% 468
2022
Q3 		$3K Buy
+11
New +$3.35K ﹤0.01% 1001

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Crewe Advisors's WST Position: Q3 2024 in Review

Crewe Advisors sold out of West Pharmaceutical (WST) in Q3 2024, closing a stake of 93 shares — an estimated $30.6K sold.

Crewe Advisors first reported a position in WST in Q3 2022 and held it in 6 quarters. The position peaked at $30.6K in Q2 2024. 730 funds tracked by Wall St. Rank hold WST as of Q3 2024.

  • Crewe Advisors reported no remaining West Pharmaceutical position as of Q3 2024 after selling out during the quarter.
  • Crewe Advisors sold 93 West Pharmaceutical shares in Q3 2024, an estimated $30.6K.
  • Crewe Advisors first reported a position in West Pharmaceutical in Q3 2022 and held it in 6 quarters.
  • Crewe Advisors's West Pharmaceutical position peaked at $30.6K in Q2 2024.
  • 730 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2024.

Based on Crewe Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.